Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement with Antion Biosciences for Multiplex miCAR™ Technology
January 11 2022 - 8:00AM
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage
biotechnology company pioneering the development of allogeneic CAR
T (AlloCAR T™) products for cancer and Antion Biosciences, a Swiss
cell and gene engineering company, today announced that they have
entered into an exclusive collaboration and global license
agreement for Antion’s miRNA technology (miCAR™) to advance
multiplex gene silencing as an additional tool to develop next
generation allogeneic CAR T products.
Antion is an early-stage research company with foundational
miRNA technology. In preclinical studies, Antion has demonstrated
proof-of-concept for multiplex gene silencing in an allogeneic CAR
T cell model. These studies demonstrated the ability of
miCAR™ technology to silence multiple gene targets in a single
step and indicate this technology has broad application within cell
and gene engineering. Allogene plans to deploy miCAR™ with
other technologies to develop next-generation strategies for immune
evasion and other advances in allogeneic CAR T therapy.
“We believe that Antion has one of the few technology options
capable of delivering multiplex gene silencing with a high degree
of specificity and potency,” said Rafael Amado, M.D., Executive
Vice President of Research and Development and Chief Medical
Officer. “We are excited to be working with Antion to explore how
their miCAR technology may advance and accelerate Allogene’s
research efforts aimed at creating best in class allogeneic cell
therapies.”
As part of this agreement, Antion will exclusively collaborate
with Allogene on oncology products for a defined period. Allogene
will also have exclusive worldwide rights to commercialize products
incorporating Antion technology developed during the collaboration.
Allogene will provide Antion an upfront cash payment and a
preferred equity investment. Allogene will pay Antion developmental
and commercial milestones and a single-digit royalty on any product
sales. Allogene will also take a seat on Antion’s Board of
Directors.
“This collaboration represents an exciting validation of the
power and flexibility of our miCAR platform,” said Sven Kili, M.D.,
Chief Executive Officer. “We are extremely enthusiastic to be
working with Allogene, as the world leader in Allogeneic CAR T
therapies to bring next-generation life changing therapies to
patients.”
About Antion Biosciences Antion Biosciences SA
is a Swiss cell and gene engineering company developing highly
innovative multiplexed allogeneic therapies to cure diseases with
significant unmet medical needs through ground-breaking cell
engineering. Antion’s proprietary Tunable Expression Modulators
(TEM) and miCAR™ technologies allow efficient, simultaneous
multi-gene silencing and gene addition in a single step, enabling
the creation of multimodal treatments that have the ability to
substantially enhance clinical safety and efficacy. These
technologies are developed using a unique Smart Data approach to
construct design and optimization, ensuring maximum efficiency.
Antion’s pipeline is focused on curing challenging cancer and
immunotherapy indications with simple, easy to administer cell
therapies.
For more information please visit: https://antion.ch/
About Allogene TherapeuticsAllogene
Therapeutics, with headquarters in South San Francisco, is a
clinical-stage biotechnology company pioneering the development of
allogeneic chimeric antigen receptor T cell (AlloCAR T™) products
for cancer. Led by a management team with significant experience in
cell therapy, Allogene is developing a pipeline of “off-the-shelf”
CAR T cell product candidates with the goal of delivering readily
available cell therapy on-demand, more reliably, and at greater
scale to more patients. For more information, please visit
www.allogene.com, and follow @AllogeneTx on Twitter and
LinkedIn.
Allogene’s Cautionary Note on Forward-Looking
Statements This press release contains forward-looking
statements for purposes of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. The press release
may, in some cases, use terms such as "predicts," "believes,"
"potential," "proposed," "continue," "estimates," "anticipates,"
"expects," "plans," "intends," "may," "could," "might," "will,"
"should" or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding intentions,
beliefs, projections, outlook, analyses or current expectations
concerning, among other things: the ability to progress the
research collaboration, Antion’s ability to develop a
next-generation approach to immune evasion, the ability to develop
and manufacture new therapies from Antion technology, and the
potential benefits of Antion technology and AlloCAR T therapy.
Various factors may cause differences between Allogene’s
expectations and actual results as discussed in greater detail in
Allogene’s filings with the SEC, including without limitation in
its Form 10-Q for the quarter ended September 30, 2021. Any
forward-looking statements that are made in this press release
speak only as of the date of this press release. Allogene assumes
no obligation to update the forward-looking statements whether as a
result of new information, future events or otherwise, after the
date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.miCAR™
is a trademark of Antion Biosciences SA.
Antion Biosciences Contact:Consilium
Strategic Communications Matthew Neal / Chris Gardner /
Ashley Tapp +44 (0)20 3709 5700antion@consilium-comms.com
Allogene Media/Investor Contact:Christine
CassianoChief Communications Officer(714)
552-0326Christine.Cassiano@allogene.com
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Apr 2024 to May 2024
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From May 2023 to May 2024